Solid Biosciences Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Solid Biosciences's estimated annual revenue is currently $10.5M per year.(i)
  • Solid Biosciences received $133.7M in venture funding in February 2018.
  • Solid Biosciences's estimated revenue per employee is $99,714
  • Solid Biosciences's total funding is $366.3M.
  • Solid Biosciences's current valuation is $155M. (January 2022)

Employee Data

  • Solid Biosciences has 105 Employees.(i)
  • Solid Biosciences grew their employee count by -24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne muscular dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Solid Biosciences News

2022-04-19 - Solid Biosciences Management to Host Call on April 27, 2022 to ...

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with...

2022-04-06 - Zacks: Analysts Expect Solid Biosciences Inc. (NASDAQ:SLDB) Will ...

Three analysts have issued estimates for Solid Biosciences' earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate...

2022-03-30 - Is it Time to Dump Solid Biosciences Inc (SLDB) Stock After it Is Down 0.00% in a Week?

Solid Biosciences Inc (SLDB) stock is unchanged 0.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Solid Biosciences Funding

DateAmountRoundLead InvestorsReference
2015-11-04$42.5MBerceptive Advisors, LLCArticle
2017-03-31$50.0MCRA Capital ManagementArticle
2018-02-01$133.7MUndisclosedJ.P. MorganArticle